Home > Insider Trading > Filing (0001209191-21-056049)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1693415	Translate Bio Inc.	TBIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1575933	Owen Hughes	C/O Translate Bio, Inc. 29 Hartwell Ave Lexington MA 02421		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-14	29,860	$38.00	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-09-14	38,135	$0.00	38,135	$7.39
Common Stock	Stock Option (right to buy)	Disposition	2021-09-14	18,900	$0.00	18,900	$10.20
Common Stock	Stock Option (right to buy)	Disposition	2021-09-14	18,900	$0.00	18,900	$15.33
Common Stock	Stock Option (righ to buy)	Disposition	2021-09-14	20,000	$0.00	20,000	$20.43

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2027-12-21	No	4	S	Direct
2029-06-17	No	4	S	Direct
2030-06-15	No	4	S	Direct
2031-06-15	No	4	S	Direct

Footnotes

As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
The shares underlying this option became fully vested on March 9, 2021.
This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020.
This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.
This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.